Clinical trial
Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal…
NCT00240019 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00240019 |
|---|---|
| Title | Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease. |
| Official title | Maximizing the Benefit of RAS Blockade in Diabetic Nephropathy |
| Lead sponsor | Stanford University, Other |
| Collaborators | National Institutes of Health (NIH) NIH |
| Status | Completed |
| Study type | Interventional |
| Conditions | Diabetic Nephropathy |
| Intervention type | Drug |
| Interventions | Addition of furosemide 20 mg oral bid to baseline regimen |
| Enrollment | 30 |
| Start date | Dec 1, 2003 |
| Completion | Apr 1, 2006 |
| First posted | Oct 17, 2005 |
| Last update posted | Oct 17, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: